PPD unveils new additions in a number of therapeutic areas

Doctors talking
PPD announced several new hires, expanding its therapeutics areas in neuroscience, hematology/oncology, rare diseases and pediatrics. (Getty/wmiami)

CRO Pharmaceutical Product Development (PPD) unveiled a number of new hires as part of the company’s goal to expand several therapeutics areas, including neuroscience, hematology/oncology, rare diseases and pediatrics.

The additions include Amy Chappell, M.D., and Alberto Lledó, M.D., Ph.D. Both Chappell and Lledó work in the area of neuroscience. Timothy Miller, M.D., was added in rare diseases and pediatrics, and Konstantin Stoitchkoy, M.D., Ph.D. in hematology/oncology. All have extensive experience in product development and commercialization, the company said.

“As the drug development process continues to become more complex, our clients are looking to PPD to provide medical and scientific expertise and strategic direction that extend far beyond traditional clinical trial implementation,” Rob Dow, PPD’s chief medical officer, said in a statement.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

Earlier this year, PPD and its patient-recruitment business unit, Acurian, launched a “patient concierge” service as part of an effort to increase trial enrollment and retention. The program proactively guides participants for the duration of a clinical study and manages their logistics, including appointment and medication reminders, device training, transportation and reimbursement support.


Suggested Articles

Ovation.io reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.